Keyword: Harvard Medical School
A PureTech startup is developing an immune-responsive hydrogel that releases a corticosteroid into arthritic joints based on their level of inflammation.
Scientists at Dana-Farber Cancer Institute and Harvard have invented an immunotherapy “gel” that’s placed at the surgery site and is showing promising results in mouse models.
An improved understanding of dopamine release in the healthy brain could lead to better treatments for addiction.
A Stanford team aimed at host cells to fight flaviviruses, while Harvard scientists examined the longevity of Zika vaccines.
Biotech news over the last week included a reversible sealant to shore up eye injuries and a promising gene therapy for the immune disorder known as "bubble boy" disease.
Outcome Health has tapped Harvard Health Publications to improve and expand its health intelligence offerings.
Researchers at Boston Children’s Hospital have discovered an approach that could suppress a tumor’s growth by altering its metabolism.
Scientists at Beth Israel Deaconess Medical Center are discovering why the process of feeling too full to eat any more goes awry in some people.
Verily hired former FDA chief Robert Califf, Theranos named a former Abbott Diagnostics exec as head of product development, Biogen's CSO quietly stepped down, and Pfizer poached Lilly's R&D exec.
Harvard professor Timothy Springer spoke to FierceBiotechResearch about the new Institute for Protein Innovation, which he created to further the development of antibodies targeting proteins that reside outside of cell walls.